

Accepted Manuscript


Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in *in vitro* and *in vivo* models of Parkinson's disease

Asma Lamine-Ajili, Ahmed M. Fahmy, Myriam Létourneau, David Chatenet, Patrick Labonté, David Vaudry, Alain Fournier

PII: S0925-4439(16)00006-5
DOI: doi: [10.1016/j.bbadis.2016.01.005](https://doi.org/10.1016/j.bbadis.2016.01.005)
Reference: BBADIS 64402

To appear in: *BBA - Molecular Basis of Disease*

Received date: 17 September 2015
Revised date: 10 December 2015
Accepted date: 4 January 2016



Please cite this article as: Asma Lamine-Ajili, Ahmed M. Fahmy, Myriam Létourneau, David Chatenet, Patrick Labonté, David Vaudry, Alain Fournier, Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in *in vitro* and *in vivo* models of Parkinson's disease, *BBA - Molecular Basis of Disease* (2016), doi: [10.1016/j.bbadis.2016.01.005](https://doi.org/10.1016/j.bbadis.2016.01.005)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in *in vitro* and *in vivo* models of Parkinson's disease¹

Asma Lamine-Ajili^{a,b,c,d}, Ahmed M. Fahmy^{a,d}, Myriam Létourneau^{a,c}, David Chatenet^{a,e},
Patrick Labonté^{a,e}, David Vaudry^{b,c,e} and Alain Fournier^{a,c,e,*}

^a INRS – Institut Armand-Frappier, 531 boul. des Prairies, Laval, QC, Canada H7V 1B7

^b INSERM-U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, IRIB, Université de Rouen, 76821 Mont-Saint-Aignan, France

^c Laboratoire Samuel-de-Champlain – Université de Rouen, France / INRS, Canada

^d Equal contribution

^e Co-senior authors

* Corresponding author: Pr. Alain Fournier, Institut national de la recherche scientifique, INRS – IAF, 531 boul. des Prairies, Laval, QC, Canada H7V 1B7
Phone : 1-450-687-5010 ext. 8816
E-mail : alain.fournier@iaf.inrs.ca

¹ **Abbreviations:** Akt: protein kinase B; Bcl-2: B-cell lymphoma 2 anti-apoptotic protein; DA: dopaminergic; DAPI: 2-(4-Amidinophenyl)-1H-indole-6-carboxamide hydrochloride; FBS: fetal bovine serum; GFP: green fluorescent protein; JNK: c-Jun N-terminal kinase; LC3 I and II: microtubule-associated protein light chain 3 I and II; MAPK: mitogen-activated protein kinase; MPP⁺: 1-methyl-4-phenylpyridinium; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MTP: mitochondrial transmembrane potential; MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; PAC1: PACAP receptor; PACAP: pituitary adenylate cyclase-activating polypeptide; PACAP38 or P38: 38-amino acid isoform of PACAP; PD: Parkinson's disease; PFA: paraformaldehyde; ROS: reactive oxygen species; SN: *substantia nigra*; SNpc: *substantia nigra pars compacta*; TBST: Tris-buffered saline with Tween 20; TH: tyrosine hydroxylase; VIP: vasoactive intestinal peptide; VPAC1: VIP/PACAP type 1 receptor; VPAC2: VIP/PACAP type 2 receptor.

Download English Version:

<https://daneshyari.com/en/article/8259500>

Download Persian Version:

<https://daneshyari.com/article/8259500>

[Daneshyari.com](https://daneshyari.com)